110 related articles for article (PubMed ID: 16934020)
1. Production and characterization of monoclonal antibodies against insulin-like growth factor type 1 receptor.
Keyhanfar M; Forbes BE; Cosgrove LJ; Wallace JC; Booker GW
Hybridoma (Larchmt); 2006 Aug; 25(4):230-7. PubMed ID: 16934020
[TBL] [Abstract][Full Text] [Related]
2. Precise mapping of an IGF-I-binding site on the IGF-1R.
Keyhanfar M; Booker GW; Whittaker J; Wallace JC; Forbes BE
Biochem J; 2007 Jan; 401(1):269-77. PubMed ID: 16981855
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
[TBL] [Abstract][Full Text] [Related]
4. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
5. Generation of a monoclonal antibody against the extracellular domain of IGF-1R.
Nakadate Y; Yoshimura S; Nakatani N; Azuma M; Tachibana T
Monoclon Antib Immunodiagn Immunother; 2014 Apr; 33(2):126-8. PubMed ID: 24746154
[TBL] [Abstract][Full Text] [Related]
6. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors.
Pandini G; Wurch T; Akla B; Corvaia N; Belfiore A; Goetsch L
Eur J Cancer; 2007 May; 43(8):1318-27. PubMed ID: 17451939
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR.
Denley A; Bonython ER; Booker GW; Cosgrove LJ; Forbes BE; Ward CW; Wallace JC
Mol Endocrinol; 2004 Oct; 18(10):2502-12. PubMed ID: 15205474
[TBL] [Abstract][Full Text] [Related]
9. Production of monoclonal antibodies recognising different epitopes present on insulin-like growth factor 1.
Harvey D; Jones WT; Jones SD; Ryan GB
Hybridoma; 1993 Dec; 12(6):737-44. PubMed ID: 7507085
[TBL] [Abstract][Full Text] [Related]
10. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody to the type 1 insulin-like growth factor and insulin receptors stimulates deoxyribonucleic acid synthesis in human and murine fibroblasts.
Cara JF; Stuart CA; Furlanetto RW
Endocrinology; 1988 Sep; 123(3):1341-7. PubMed ID: 2969801
[TBL] [Abstract][Full Text] [Related]
12. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
13. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor.
Li J; Lundberg E; Vernet E; Larsson B; Höidén-Guthenberg I; Gräslund T
Biotechnol Appl Biochem; 2010 Feb; 55(2):99-109. PubMed ID: 20088825
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a chimeric monoclonal antibody against the insulin-like growth factor-I receptor.
Zhang MY; Feng Y; Wang Y; Dimitrov DS
MAbs; 2009; 1(5):475-80. PubMed ID: 20065647
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
17. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity.
Soos MA; Field CE; Lammers R; Ullrich A; Zhang B; Roth RA; Andersen AS; Kjeldsen T; Siddle K
J Biol Chem; 1992 Jun; 267(18):12955-63. PubMed ID: 1377676
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
[TBL] [Abstract][Full Text] [Related]
19. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers.
Rubini M; D'Ambrosio C; Carturan S; Yumet G; Catalano E; Shan S; Huang Z; Criscuolo M; Pifferi M; Baserga R
Exp Cell Res; 1999 Aug; 251(1):22-32. PubMed ID: 10438568
[TBL] [Abstract][Full Text] [Related]
20. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
